$1.79
1.65% day before yesterday
Nasdaq, Dec 27, 09:47 pm CET
ISIN
US0144421072
Symbol
ALEC
Sector
Industry

Alector, Inc. Stock price

$1.78
-0.77 30.06% 1M
-2.76 60.79% 6M
-6.20 77.69% YTD
-6.17 77.61% 1Y
-20.84 92.13% 3Y
-15.82 89.89% 5Y
-14.85 89.30% 10Y
Nasdaq, Closing price Fri, Dec 27 2024
-0.04 2.20%
ISIN
US0144421072
Symbol
ALEC
Sector
Industry

Key metrics

Market capitalization $174.32m
Enterprise Value $-248.24m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 1.12
EV/Sales (TTM) EV/Sales -4.04
P/S ratio (TTM) P/S ratio 2.83
P/B ratio (TTM) P/B ratio 1.47
Revenue growth (TTM) Revenue growth -36.14%
Revenue (TTM) Revenue $61.51m
EBIT (operating result TTM) EBIT $-185.20m
Free Cash Flow (TTM) Free Cash Flow $-222.26m
Cash position $457.20m
EPS (TTM) EPS $-1.71
P/E forward negative
P/S forward 2.65
EV/Sales forward negative
Short interest 7.83%
Show more

Is Alector, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.

Alector, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

10 Analysts have issued a Alector, Inc. forecast:

6x Buy
60%
2x Hold
20%
2x Sell
20%

Analyst Opinions

10 Analysts have issued a Alector, Inc. forecast:

Buy
60%
Hold
20%
Sell
20%

Financial data from Alector, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
62 62
36% 36%
100%
- Direct Costs 9.02 9.02
4% 4%
15%
52 52
40% 40%
85%
- Selling and Administrative Expenses 50 50
16% 16%
82%
- Research and Development Expense 178 178
9% 9%
290%
-176 -176
17% 17%
-286%
- Depreciation and Amortization 9.02 9.02
4% 4%
15%
EBIT (Operating Income) EBIT -185 -185
16% 16%
-301%
Net Profit -158 -158
12% 12%
-258%

In millions USD.

Don't miss a Thing! We will send you all news about Alector, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Alector, Inc. Stock News

Neutral
GlobeNewsWire
about one month ago
SOUTH SAN FRANCISCO, Calif., Nov. 25, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering novel, genetically validated therapies for the treatment of neurodegenerative diseases, today announced results from the INVOKE-2 Phase 2 clinical trial evaluating the safety and efficacy of AL002 in slowing disease progression in individuals with early ...
Neutral
GlobeNewsWire
about one month ago
SOUTH SAN FRANCISCO, Calif., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that the Company has entered into a debt financing agreement with Hercules Capital, Inc. (NYSE: HTGC) for up to $50 million.
Neutral
GlobeNewsWire
about 2 months ago
Data from INVOKE-2, evaluating TREM2 agonist candidate AL002 in patients with early Alzheimer's disease (AD), on track for 2024
More Alector, Inc. News

Company Profile

Alector, Inc. operates as a clinical-stage biopharmaceutical company. It develops therapeutics for the treatment of neurodegenerative diseases including frontotemporal dementia (FTD), Alzheimer's disease, and Parkinson's disease. The company was founded by Asa Abeliovich, Errik B. Anderson, Tillman U. Gerngross, and Arnon Rosenthal in May 2013 and is headquartered in South San Francisco, CA.

Head office United States
CEO Arnon Rosenthal
Employees 244
Founded 2013
Website www.alector.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today